Skip to main content

Table 2 Adverse events associated with chemotherapy

From: Outcomes of esophagectomy after chemotherapy with biweekly docetaxel plus cisplatin and fluorouracil for advanced esophageal cancer: a retrospective cohort analysis

  DCF, N = 37 bDCF, N = 22 p value
Number of coursesa 2.3 ± 1.3 2.7 ± 1.2 0.303
Discontinuance of next course due to AE 6 (16.2) 2 (9.1) 0.440
Dose reduction 8 (21.6) 3 (13.6) 0.446
Hematologic toxicity (grades 3–4)
 Neutropenia 30 (81.1) 9 (40.9) 0.002
 Febrile neutropenia 5 (13.5) 2 (9.1) 0.612
 Anemia 1 (2.7) 0 0.437
 Thrombocytopenia 1 (2.7) 0 0.437
Non-hematologic toxicity (grades 3–4)
 Nausea/vomiting 1 (2.7) 1 (4.5) 0.705
 Diarrhea 10 (27) 5 (22.7) 0.714
 Mucositis oral 6 (16.2) 1 (4.5) 0.180
 Anorexia 7 (18.9) 0 0.030
Days to operationab (range) 52.3 ± 14.7 (30–86) 45.1 ± 13.5 (30–83) 0.067
Preoperative white blood cell count (/μL)a 5929.2 ± 2094 5017.3 ± 1777.7 0.091
Preoperative neutrophil count (/μL)a 3529.9 ± 1819.5 2950.2 ± 1313.1 0.199
  1. AE adverse events
  2. aMean ± standard deviation
  3. bTime period between day 1 at last course of chemotherapy and operation